Alto Neuroscience (ANRO) grants director stock options in lieu of $50K fees

Rhea-AI Filing Summary

Alto Neuroscience, Inc. director compensation is disclosed through a new stock option grant. On 01/02/2026, a reporting person serving as a director received an employee stock option to buy 4,228 shares of common stock at an exercise price of $16.59 per share. The option relates to 4,228 underlying common shares and was granted under the company’s Non-Employee Director Compensation Policy in lieu of $50,000 in cash retainer fees. The option vests in four equal installments of 1,057 shares on March 31, 2026, June 30, 2026, September 30, 2026 and December 31, 2026, if the director’s service continues through each vesting date.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Manji Husseini

(Last) (First) (Middle)

C/O ALTO NEUROSCIENCE, INC.

650 CASTRO STREET, SUITE 450

(Street)

MOUNTAIN VIEW CA 94041

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Alto Neuroscience, Inc. [ ANRO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
01/02/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (right to buy)	$16.59	01/02/2026		A		4,228		(1)	01/01/2036	Common Stock	4,228	$11.82	4,228(2)	D

Explanation of Responses:

1. 1,057 shares underlying the option shall vest on each of March 31, 2026, June 30, 2026, September 30, 2026 and December 31, 2026, subject to the Reporting Person's continuous service through each such vesting date.

2. This option was issued to the Reporting Person pursuant to the Issuer's Non-Employee Director Compensation Policy in lieu of retainer fees of $50,000.

Remarks:

	/s/ Erin R. McQuade, Attorney-in-Fact	01/06/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Alto Neuroscience (ANRO) report in this Form 4?

Alto Neuroscience reported that a director received an employee stock option to purchase 4,228 shares of common stock on 01/02/2026 as part of director compensation.

What is the exercise price of the Alto Neuroscience (ANRO) director stock options?

The employee stock option granted to the director has an exercise price of $16.59 per share for the underlying Alto Neuroscience common stock.

How many Alto Neuroscience (ANRO) shares underlie the new director stock option?

The granted employee stock option covers 4,228 shares of Alto Neuroscience common stock, matching the number of derivative securities acquired.

How and when do the Alto Neuroscience (ANRO) director options vest?

The option vests in four equal installments of 1,057 shares on March 31, 2026, June 30, 2026, September 30, 2026 and December 31, 2026, subject to continued service.

Why was this Alto Neuroscience (ANRO) stock option granted to the director?

The option was issued under the company’s Non-Employee Director Compensation Policy in lieu of cash retainer fees totaling $50,000.

Is the Alto Neuroscience (ANRO) insider transaction filed for one or multiple reporting persons?

The report indicates that the Form is filed by one reporting person, reflecting that individual director’s option grant.